Home Nav
Nextech Invest Logo

Paul Workman

Alfred Scheidegger

Paul Workman PhD DSc (Hon) FRS FMedSci FSB FRSC is the Chief Executive and President of The Institute of Cancer Research (ICR) in London UK. He is also Harrap Professor of Pharmacology and Therapeutics and Director of the Cancer Research UK (CRUK) Centre at the ICR and Royal Marsden. From 1997 to 2016 Dr Workman was Head of the ICR’s Division of Cancer Therapeutics and Director of the CRUK Cancer Therapeutics Unit – the world’s largest academic cancer drug discovery centre. He has been elected a Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society of Medicine, Fellow of the Society of Biology, Fellow of the Royal Society of Chemistry and Fellow of the European Academy of Cancer Sciences and he is CRUK Life Fellow. He was formerly Biology Section Head of Cancer Research, AstraZeneca Ltd. Dr Workman was also the scientific founder of two oncology companies and has served as a consultant to many others. He has won a number of awards for his discovery and development of new cancer drugs. He is a Cancer Research UK Life Fellow and winner of the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy and the 2012 Royal Society of Chemistry World Entrepreneur of the Year Award.


Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

06.09. – 09.09.2017

Mainz/Frankfurt, Germany

  • 25.07.2017

    Santen and TRACON announce initiation of a phase IIa...

  • 18.07.2017

    Kura Oncology announces issuance of U.S. patent for...

  • 13.07.2017

    Kura Oncology establishes collaboration with Foundation...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.